The Frusemide and Diamox Evaluation in ICU (FADE ICU) Study

Not Applicable

Completed

• Conditions: Kidney disease; Renal and Urogenital - Kidney disease

• Registration Number: ACTRN12617000566336
• Lead Sponsor: Austin Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-04-24
• Last Update Posted: 14 January 2019

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

Admission to the Austin Hospital ICU
Age 18 years or greater
An attending physician’s decision to administer a diuretic
An anticipated ICU length of stay of >24 hours after frusemide administration
Patients with existing intra-arterial cannulae or central venous catheters for blood sampling, and indwelling urinary catheters.

Exclusion Criteria

Patients with known allergy to frusemide or acetazolamide or other sulphonamides.
Known existing end stage renal failure
Long-standing use of diuretic therapy
Dose of different diuretic in the preceding 12 hours.
Significant pre-existing acid-base disturbance at time of enrolment (pH < 7.30 or > 7.50)
Patient receiving continuous renal-replacement therapy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
rine volume[Volume of urine documented in the six hour period from the diuretic being administered as recorded in the patient's medical record]